During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Viatris Inc (NASDAQ:VTRS)

  • Dividend Yield: 2.93%
  • Barclays analyst Glen Santangelo maintained an Overweight rating and raised the price target from $17 to $22 on May 19, 2026. This analyst has an accuracy rate of 58%.
  • JP Morgan analyst Chris Scott maintained a Neutral rating and increased the price target from $17 to $18 on May 8, 2026. This analyst has an accuracy rate of 65%.
  • Recent News: Viatris said it will report second-quarter financial results on Thursday, Aug. 6.
  • Benzinga Pro’s real-time newsfeed alerted to latest VTRS news.

Medtronic PLC (NYSE:MDT)

  • Dividend Yield: 3.45%
  • TD Cowen analyst Joshua Jennings maintained a Buy rating and slashed the price target from $119 to $100 on July 10, 2026. This analyst has an accuracy rate of 54%.
  • Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating and cut the price target from $106 to $105 on July 6, 2026. This analyst has an accuracy rate of 54%
  • Recent News: The FDA announced that Medtronic has recalled certain Harmony delivery catheter system.
  • Benzinga Pro’s real-time newsfeed alerted to latest MDT news

GSK plc (NYSE:GSK)

  • Dividend Yield: 3.43%
  • Barclays analyst James Gordon downgraded the stock from Equal-Weight to Underweight on Jan. 6, 2026. This analyst has an accuracy rate of 72%
  • Jefferies analyst Michael Leuchten upgraded the stock from Hold to Buy on Oct. 27, 2025. This analyst has an accuracy rate of 63%.
  • Recent News: GSK on Monday reported interim results from its registrational Phase 2 AZUR-1 trial of Jemperli (dostarlimab) in rectal cancer patients.
  • Benzinga Pro’s real-time newsfeed alerted to latest GSK news

Photo via Shutterstock